Evidence map›Paper›PMID 39570032›Full record

ArticleAntimicrobial agents and chemotherapy2025

Olorofim demonstrates

Nathan P Wiederhold, Hoja P Patterson, Dora Ferrer, Victor Garcia, George R Thompson, Thomas F Patterson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Insights into current coccidioidomycosis therapeutic pathways.Antimicrobial agents and chemotherapy · 2025
    Article
  4. Article
  5. Coccidioidomycosis: a growing global concern.The Journal of antimicrobial chemotherapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nathan P WiederholdFungus Testing Laboratory, Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID 0000-0002-2225-5122
Hoja P PattersonFungus Testing Laboratory, Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Dora FerrerFungus Testing Laboratory, Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Victor GarciaFungus Testing Laboratory, Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
George R ThompsonDepartment of Medical Microbiology and Immunology, University of California Davis, Davis, California, USA.
Thomas F PattersonDivision of Infectious Diseases, Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

Funding

F2G (F2G Ltd)
6 · The paper itself

Abstract

We evaluated the

Indexed as

Antifungal AgentsCoccidioidesFluconazoleCoccidioidomycosisHumansMicrobial Sensitivity TestsAntifungal AgentsFluconazoleCoccidioides speciesfluconazolein vitro susceptibilityolorofim

Identifiers

PMID39570032
PMCPMC11784075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.